Type 1 diabetic neuropathy and C-peptide

Experimental Diabesity Research

Volumn 5, Issue 1, 2004, Pages 65-77

  Sima, Anders A F ^a,b   Zhang, Weixian ^a,b   Grunberger, George ^c  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c Grunberger Diabetes Institute   (United States)

Author keywords

Axonal degeneration; C peptide; Diabetic neuropathy; Nodal degeneration; Regeneration

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALDOSE REDUCTASE INHIBITOR; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; C PEPTIDE; CHELATING AGENT; DEFEROXAMINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FISH OIL; GAMMA LINOLENIC ACID; INSULIN; LEVACECARNINE; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR; NEUROTROPHIN 3; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PLACEBO; PRIMROSE OIL; SOMATOMEDIN; SOMATOMEDIN B; THIOCTIC ACID; TRIENTINE;

APOPTOSIS; AUTONOMIC NERVE; BLOOD FLOW; DEGENERATIVE DISEASE; DIABETIC NEUROPATHY; DISEASE SEVERITY; DOSE RESPONSE; DRUG SCREENING; ENDONEURIUM; ENZYME ACTIVITY; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NERVE CONDUCTION; NERVE FIBER REGENERATION; NERVE FUNCTION; NERVOUS SYSTEM INJURY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW;

ANIMALS; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; HUMANS; INSULIN; NERVE DEGENERATION; NERVE GROWTH FACTORS; NERVE REGENERATION; NERVOUS SYSTEM;

EID: 1842791603     PISSN: 15438600     EISSN: None     Source Type: Journal    
DOI: 10.1080/15438600490424541     Document Type: Review

References (132)

1. Apfel, S. C. (1999) Neurotrophic factors in the therapy of diabetic neuropathy. Am. J. Med., 107, 34S-42S.
2. Apfel, S. C., Arezzo, J. C., Brownlee, M., Federoff, H., and Kessler, J. A. (1994) Nerve growth factor administration protects against experimental diabetic sensory neuropathy. Brain Res., 634, 7-12.
3. Araki, N., Ueno, N., Chakrabarti, B., Morino, Y., and Horiuchi, S. (1992) Immunochemical evidence for the presence of advanced glycation end products in human lens proteins and its positive correlation with aging. J. Biol. Chem., 267, 10211-10214.
4. Aruoma, O. I., Halliwell, B., Hoey, B. M., and Butler, J. (1988) The antioxidant action of taurine, hypotaurine and their metabolic precursors. Biochem. J., 256, 251-255.
5. Baynes, J. W. (1991) Role of oxidative stress in development of complications in diabetes. Diabetes, 40, 405-412.
6. Beisswenger, P. J., Moore, L. L., Brinck-Johnsen, T., and Curphey, T. J. (1993) Increased collagen-linked pentosidine levels and advanced glycosylation end products in early diabetic nephropathy. J. Clin. Invest., 92, 2212-2217.
7. Bierhaus, A., Chevion, S., Chevion, M., Hofmann, M., Quehenberger, P., Illmer, T., et al. (1997) Advanced glycation end product-induced activation of NF-κB is suppressed by a-lipoic acid in cultured endothelial cells. Diabetes, 46, 1481-1490.
8. Brewster, W. J., Fernyhough, P., Diemel, L. T., Mohiuddin, L., and Tomlinson, D. R. (1994) Diabetic neuropathy, nerve growth factor and other neurotrophic factors. Trends Neurosci., 17, 321-325.
9. Brismar, T., and Sima, A. A. F. (1981) Changes in nodal function in nerve fibres of the spontaneously diabetic BB-Wistar rat. Potential clamp analysis. Acta Physiol. Scand., 113, 499-506.
10. Brismar, T., Sima, A. A. F., and Greene, D. A. (1987) Reversible and irreversible nodal dysfunction in diabetic neuropathy. Ann. Neurol., 21, 504-507.
11. Brownlee, M. (2001) Biochemistry and molecular cell biology of diabetic complications. Nature, 414, 813-820.
12. Cameron, N. E., and Cotter, M. A. (1995) Neurovascular dysfunction in diabetic rats. Potential contribution of autoxidation and free radicals examined using transition metal chelating agents. J. Clin. Invest., 96, 1159-1163.
13. Cotter, M., Ekberg, K., Wahren, J., and Cameron, N. E. (2003) Effects of proinsulin C-peptide in experimental diabetic neuropathy. Diabetes, 52, 1812-1817.
14. +-channel displacement is associated with nerve conduction slowing in the chronically diabetic BB/W-rat. Prevention by an aldose reductase inhibitor. J. Diabetes Complication, 10, 192-200.
15. Crosby, S. R., Tsigos, C., Anderton, C. D., Gordon, C., Young, R. J., and White, A. (1992) Elevated plasma insulin-like growth factor binding protein-1 levels in type 1 (insulin-dependent) diabetic patients with peripheral neuropathy. Diabetologia, 35, 868-872.
16. Cullum, N. A., Mahon, J., Stringer, K., and McLean, W. G. (1991) Glycation of rat sciatic nerve tubulin in experimental diabetic mellitus. Diabetologia, 34, 387-389.
17. Diemel, L. T., Brewster, W. J., Fernyhough, P., and Tomlinson, D. R. (1994) Expression of neuropeptides in experimental diabetes; effects of treatment with nerve growth factor or brain-derived neurotrophic factor. Brain Res. Mol. Brain. Res., 21, 171-175.
18. Dyck, P. J., Davies, J. L., Wilson, D. M., Service, F. J., Melton, L. J. III, and O'Brien, P. C. (1999) Risk factors for severity of diabetic polyneuropathy: Intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study Cohort. Diabetes Care, 22, 1479-1486.
19. Dyck, P. J. B., and Dyck, P. J. (1999) Diabetic polyneuropathy. In: Diabetic Neuropathy, 2nd ed., Edited by Dyck, P. J., and Thomas, P. K., pp. 255-278. Philadelphia, W.B. Saunders.
20. Ebendal, T. (1992) Function and evolution in the NGF family and its receptors. J. Neurosci. Res., 32, 461-470.
21. Ekberg, K., Brismar, T., Johansson, B.-L., Jonsson, B., Lindström, P., and Wahren, J. (2003) Amelioration of sensory nerve dysfunction by C-peptide in patients with type 1 diabetes. Diabetes, 52, 536-541.
22. Einheber, S., Zanazzi, G., Ching, W., Scheres, S., Milner, T. A., Peles, E., et al. (1997) The axonal membrane Caspr, a homologue of neurexin IV, is a component of the septate-like paranodal junctions that assemble during myelination. J. Cell Biol., 139, 1495-1506.
23. Ernfors, P., Lee, K. F., Kucera, J., and Jaenisch, R. (1994) Lack of neurotrophin-3 leads to deficiencies in the peripheral nervous system and loss of limb proprioceptive afferents. Cell, 77, 503-512.
24. Federoff, H. J., Lawrence, D., and Brownlee, M. (1993) Nonenzymatic glycosylation of laminin and laminin peptide CIKVAVS inhibits neurite outgrowth. Diabetes, 42, 509-513.
25. Feldman, E. L. (2003) Oxidative stress and diabetic neuropathy: A new understanding of an old problem. J. Clin. Invest., 111, 431-433.
26. Fernyhough, P., Diemel, L. T., and Tomlinson, D. R. (1998) Target tissue production and axonal transport of neurotrophin-3 are reduced in streptozotocin-diabetic rats. Diabetologia, 41, 300-306.
27. + ATPase activity in diabetes mellitus type 1. Clin. Sci., 98, 283-290.
28. Forst, T., and Kunt, T. (2004) Effects of C-peptide on microvascular blood flow and blood haemorheology. J. Diabesity Res., (this issue).
29. Forst, T., Kunt, T., Pohlmann, T., Goitom, K., Engelbach, M., Beyer, J., et al. (1998a) Biological activity of C-peptide on skin microcirculation in patients with insulin-dependent diabetes mellitus. J. Clin. Invest., 101, 2036-2041.
30. Forst, T., Kunt, T., Pfutzner, A., Beyer, J., and Wahren, J. (1998b) New aspects on biological activity of C-peptide in IDDM patients. Exp. Clin. Endocrinol. Diabetes, 106, 270-276.
31. Greene, D. A., Lattimer, S. A., and Sima, A. A. F. (1987) Sorbitol, phosphoinositides and sodium-potassium ATPase in the pathogenesis of diabetic complications. N. Engl. J. Med., 316, 599-606.
32. Greene, D. A., Sima, A. A. F., Feldman, E. L., and Stevens, M. J. (1997) Diabetic neuropathy. In: Ellenberg and Rifkin Diabetes Mellitus, Edited by Rifkin, H., Porte, D., and Sherwin, R., pp. 1009-1076 Stanford, CT, Appleton and Lange.
33. Greene, D. A., Sima, A. A. F., Stevens, M., Feldman, E., Killen, P., Henry, D., Thomas, T., Dannenberg, J., and Lattimer, S. A. (1993) Aldose reductase inhibitors: An approach to the treatment of the nerve damage of diabetic neuropathy. Diabetes Metab. Rev., 9, 189-217.
34. Greene, D. A., Sima, A. A. F., Stevens, M. J., Feldman, E. L., and Lattimer, S. A. (1992) Complications: Neuropathy, pathogenetic considerations. Diabetes Care, 15, 1902-1925.
35. Grunberger, G., Qiang, X., Li, Z.-G., Mathews, S. T., Sbriessa, D., Shisheva, A., et al. (2001) Molecular basis for the insulinomimetic effects of C-peptide. Diabetologia, 44, 1247-1257.
36. Grunberger, G., and Sima, A. A. F. (2004) The C-peptide signaling. J. Diabesity Res., 5, 25-36.
37. Hammes, H. P., Alt, A., Niwa, T., Clausen, J. T., Bretzel, R. G., Brownlee, M., et al. (1999) Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. Diabetologia, 42, 728-736.
38. Heesom, A. E., Millward, A., and Demaine, A. G. (1998) Susceptibility to diabetic neuropathy in patients with insulin dependent diabetes mellitus is associated with a polymorphism at the 5′ end of the aldose reductase gene. J. Neurol. Neurosurg. Psychiatry, 64, 213-216.
39. Hellweg, R., and Hartung, H. D. (1990) Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus: A possible role for NGF in the pathogenesis of diabetic neuropathy. J. Neurosci. Res., 26, 258-267.
40. Hengerer, B., Lindholm, D., Henmann, R., Ruther, V., Wagner, E. F., and Thoenen, H. (1990) Lesion-induced increase in nerve growth factor mRNA is mediated by c-fos. Proc. Natl. Acad. Sci. U. S. A., 87, 3899-3903.
41. Hory-Lee, F., Russell, M., Lindsay, R. M., and Frank, E. (1993) Neurotrophin 3 supports the survival of developing muscle sensory neurons in culture. Proc. Natl. Acad. Sci. U. S. A., 90, 2613-2617.
42. Hruska, R. E., Chertak, M. M., and Kravis, D. (1993) Elevation of nerve growth factor receptor - truncated in the urine of patients with diabetic neuropathy. Ann. N. Y. Acad. Sci., 679, 349-351.
43. Hunt, J. V., Dean, R. T., and Wolff, S. P. (1988) Hydroxyl radical production and autoxidative glycation. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and aging. Biochem. J., 256, 205-212.
44. Hunt, J. V., and Wolff, S. P. (1991) Oxidative glycation and free radical production: A causal mechanism of diabetic complications. Free Radic. Res. Commun., 12-13, 115-123.
45. Ide, C. (1996) Peripheral nerve regeneration. Neurosci. Res., 25, 101-121.
46. Ishii, D. N. (1995) Implication of insulin-like growth factors in the pathogenesis of diabetic neuropathy. Brain Res. Rev., 20, 47-67.
47. Ishii, D. N., Guertin, D. M., and Whalen, L. R. (1994) Reduced insulin-like growth factor-I mRNA content in liver, adrenal glands and spinal cord of diabetic rats. Diabetologia, 37, 1073-1081.
48. Ishii, H., Koya, D., and King, G. L. (1998) Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus. J. Mol. Med., 76, 21-31.
49. Ishii, D. N., and Lupien, S. B. (1995) Insulin-like growth factors protect against diabetic neuropathy: Effects on sensory nerve regeneration in rats. J. Neurosci. Res., 40, 138-144.
50. Isom, L. L. (2002) The role of sodium channels in cell adhesion. Front Biosci., 7, 12-23.
51. Jakobsen, J., Brimijoin, S., Skau, K., Sidenius, P., and Wells, D. (1981) Retrograde axonal transport of transmitter enzymes, fucose-labeled protein, and nerve growth factor in streptozotocin-diabetic rats. Diabetes, 30, 797-803.
52. Jensen, M. E., and Messina, E. J. (1999) C-peptide induces a concentration-dependent dilation of skeletal muscle arterioles only in presence of insulin. Am. J. Physiol., 276, H1223-H1228.
53. Johansson, B.-L., Borg, K., Fernquist-Forbes, E., Kernell, A., Odergren, T., and Wahren, J. (2000) Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with type 1 diabetes mellitus. Diabetes Med., 17, 181-189.
54. Johansson, B.-L., Kernell, A., Sjöberg, S., and Wahren, J. (1993) Influence of combined C-peptide and insulin administration on renal function and metabolic control in diabetes type 1. J. Clin. Endocrinol. Metab., 77, 976-981.
55. Johansson, B.-L., Linde, B., and Wahren, J. (1992) Effects of C-peptide on blood flow, capillary diffusion capacity and glucose utilization in the exercising forearm of type 1 (insulin-dependent) diabetic patients. Diabetologia, 35, 1151-1158.
56. Kamijo, M., Merry, A. C., Cherian, P. V., Akdas, G., and Sima, A. A. F. (1996) Nerve fiber regeneration following axotomy in the diabetic BB/W-rat. The effect of ARI-treatment. J. Diabetes Complication, 10, 183-191.
57. Lambert, S., Davis, J. Q., and Bennett, V. (1997) Morphogenesis of the node of Ranvier: Co-clusters of ankyrin and ankyrin-binding integral proteins define early developmental intermediaries. J. Neurosci., 15, 7025-7036.
58. Laudadio, C., and Sima, A. A. F. (1996) Design of controlled clinical trials for diabetic polyneuropathy. Semin. Neurol., 16, 187-192.
59. Laudadio, C., and Sima, A. A. F., and The Ponalrestat Study Group (1998) Progression rates of diabetic neuropathy in placebo patients in an 18-month clinical trial. J. Diabetes Complication, 12, 121-127.
60. Li, Z., Zhang, W., Grunberger, G., and Sima, A. A. F. (2002a) Hippocampal neuronal apoptosis in type 1 diabetes. Brain Res., 946, 212-231.
61. Li, Z.-G., Qiang, X., Sima, A. A. F., and Grunberger, G. (2001) C-peptide attenuates protein tyrosine phosphatase activity and enhances glycogen synthesis in L6 myoblasts. Biochem. Biophys. Res. Commun., 280, 615-619.
62. Li, Z.-G., Zhang, W., and Sima, A. A. F. (2002b) C-peptide prevents hippocampal apoptosis in type 1 diabetes. Int. J. Exp. Diabetes Res., 3, 241-246.
63. Li, Z.-G., Zhang, W., and Sima, A. A. F. (2003) C-peptide enhances insulin-mediated cell growth and protects against high glucose induced apoptosis in SH-SY5Y cells. Diabetes Metab. Res. Rev., 19, 375-385.
64. Low, P. A., Nickander, K. K., and Scionti, L. (1999) Role of hypoxia, oxidative stress, and excitatory neurotoxins in diabetic neuropathy. In: Diabetic Neuropathy, Edited by Dyck, P. J., and Thomas, P. K., pp. 317-329. Philadelphia, W. B. Saunders.
65. Malhotra, J. D., Kazeu-Gillespie, K., Hortsch, M., and Isom, L. L. (2000) Sodium channel β subunits mediate homophilic cell adhesion and recruit ankyrin to points of cell-cell contact. J. Biol. Chem., 275, 11383-11388.
66. McCance, D. R., Dyer, D. G., Dunn, J. A., Bailie, K. E., Thorpe, S. R., and Baynes, J. W. (1993) Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J. Clin. Invest., 91, 2470-2478.
67. McCord, J. M. (1985) Oxygen-derived free radicals in postischemic tissue injury. N. Engl. J. Med., 312, 159-163.
68. Menegoz, M., Gaspar, P., Le Bert, M., Galvez, T., Burgaya, F., Palfrey, C., et al. (1997) Paranodin, a glycoprotein of neuronal paranodal membranes. Neuron, 19, 319-331.
69. Mitchison, T., and Kirschner, M. (1988) Cytoskeletal dynamics and nerve growth. Neuron, 1, 761-772.
70. Muller-Husman, G., Gloor, S., and Schachner, M. (1993) Functional characterization of beta isoforms of murine Na/K-ATPase. The adhesion molecule on glia (AMOG/beta 2) but not beta 1, promotes neurite outgrowth. J. Biol. Chem., 268, 26260-26267.
71. New, H. V., and Mudge, A. W. (1986) Distribution and ontogeny of SP, CGRP, SOM, and VIP in chick sensory and sympathetic ganglia. Dev. Biol., 116, 337-346.
72. Oates, P. J., and Mylari, B. L. (1999) Aldose reductase inhibitors: Therapeutic implications for diabetic complications. Exp. Opinion Invest. Drugs, 8, 2095-2119.
73. Peles, E., Nativ, M., Campbell, P. L., Sukurai, T., Martinez, R., Lev, S., et al. (1995) The carbonic anhydrase domain of receptor tyrosine phosphatase beta is a functional ligand for the axonal cell recognition molecule contactin. Cell, 82, 251-260.
74. Peles, E., Nativ, M., Lustig, M., Graumet, M., Schilling, J., Martinez, R., et al. (1997) Identification of a novel contactin-associated transmembrane receptor with multiple domains implicated in protein-protein interactions. EMBO J., 16, 978-988.
75. Pierson, C. R., Zhang, W., Murakawa, Y., and Sima, A. A. F. (2002) Early gene responses of trophic factors differ in nerve regeneration in type 1 and type 2 diabetic neuropathy. J. Neuropathol. Exp. Neurol., 61, 857-871.
76. Pierson, C. R., Zhang, W., Murakawa, Y., and Sima, A. A. F. (2003a) Insulin deficiency rather than hyperglycemia accounts for impaired neurotrophic responses and nerve fiber regeneration in type 1 diabetic neuropathy. J. Neuropathol. Exp. Neurol., 63, 260-271.
77. Pierson, C. R., Zhang, W., and Sima, A. A. F. (2003b) Proinsulin C-peptide replacement in type 1 BB/Wor-rats prevents deficits in nerve fiber regeneration. J. Neuropathol. Exp. Neurol., 62, 765-779.
78. Pirart, J. (1977) Diabetes mellitus and its degenerative complications: A prospective study of 4,400 patients observed between 1947 and 1973. Diabete Metab., 3, 97-107.
79. Ratcliff, C. F., Qu, Y., McCormick, K. A., Tibbs, V. C., Dixon, J. E., Scheuer, T., et al. (2000) A sodium channel signaling complex: Modulation by associated receptor protein tyrosine phosphatase β. Nat. Neurosci., 3, 437-444.
80. Rigler, R., Pramanik, A., Jonasson, P., Kratz, G., Jansson, O. T., Nygren, P., et al. (1999) Specific binding of proinsulin C-peptide to human cell membranes. Proc. Natl. Acad. Sci. U. S. A., 96, 13318-13323.
81. Ryle, C., Leow, C. K., and Donaghy, M. (1997) Nonenzymatic glycation of peripheral and central nervous system proteins in experimental diabetes mellitus. Muscle Nerve, 20, 577-584.
82. Scherer, S. S. (1996) Molecular specialization at nodes and paranodes in peripheral nerve. Micros. Res. Techn., 34, 452-461.
83. Sell, D. R., Lapolla, A., Odetti, P., Fogarty, J., and Monnier, V. M. (1992) Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM. Diabetes, 41, 1286-1292.
84. Sima, A. A. F. (1994) Pathological definition and evaluation of diabetic neuropathy and clinical correlations. Can. J. Neurol. Sci., 21(Suppl 4), 513-517.
85. Sima, A. A. F. (1996) Metabolic alterations of peripheral nerve in diabetes. Semin. Neurol., 16, 129-137.
86. Sima, A. A. F. (1999) Diabetic neuropathy - The utility of nerve biopsy, In: Clinical Neurophysiology: From Receptors to Perception, Edited by Comi, G., Lücking, C. H., Kimura, J., Rossini, P. M., pp. 525-533. Amsterdam, Elsevier Science.
87. Sima, A. A. F. (2001) Diabetic neuropathy; pathogenetic backgrounds, current and future therapies. Expert Rev. Neurother, 1, 225-238.
88. Sima, A. A. F. (2003a) New insights into the metabolic and molecular basis for diabetic neuropathy. Cell. Mol. Life Sci., 60, 1-20.
89. Sima, A. A. F. (2003b) C-peptide and diabetic neuropathy. Expert Opin. Drug Dev., 12, 1471-1488.
90. Sima, A. A. F., Bril, V., Nathaniel, V., McEwen, T. A. J., Brown, M., Lattimer, S. A., and Greene, D. A. (1988a) Regeneration and repair of myelinated fibers in sural nerve biopsies from patients with diabetic neuropathy treated with an aldose reductase inhibitor. N. Engl. J. Med., 319, 548-555.
91. Sima, A. A. F., and Brismar, T. (1985) Reversible diabetic nerve dysfunction. Structural correlates to electrophysiological abnormalities. Ann. Neurol., 18, 21-29.
92. Sima, A. A. F., and Cherian, P. V. (1997) Neuropathology of diabetic neuropathy and its correlations with neurophysiology. Clin. Neurosci., 4, 359-364.
93. Sima, A. A. F., Grunberger, G., Jörnvall, H., Wahren, J., and The C-Peptide Study Group (2001a) Proinsulin C-peptide - A consensus statement. Int. J. Exp. Diabetes Res., 2, 145-151.
94. Sima, A. A. F., Lattimer, S. A., Yagihashi, S., and Greene, D. A. (1986) "Axo-glial dysjunction": A novel structural lesion that accounts for poorly reversible slowing of nerve conduction in the spontaneously diabetic BB-rat. J. Clin. Invest., 77, 474-484.
95. Sima, A. A. F., Li, Z., Zhang, W., and Stevens, M. (2003a) Impaired endoneurial blood flow but not oxidative stress is prevented by C-peptide in type 1 BB/Wor-rats. Brain Pathol., 12(Suppl 41).
96. Sima, A. A. F., Merry, A. C., and Lightle, R. (1997a) Impaired macrophage recruitment in axotomized diabetic nerve. Exp. Clin. Endocrinol Diabetes., 105, 62-63.
97. Sima, A. A. F., Nathaniel, V., Bril, V., McEwen, T. A. J., and Greene, D. A. (1988b) Histopathological heterogeneity of neuropathy in insulin-dependent and non-insulin-dependent diabetes, and demonstration of axo-glial dysjunction in human diabetic neuropathy. J. Clin. Invest., 81, 349-364.
98. Sima, A. A. F., Pierson, C. R., and Zhang, W. (2002) C-peptide prevents the molecular abnormalities of the paranode in type 1 diabetic polyneuropathy (DPN). Presented at the 18th International Diabetes Federation Congress, Paris, abstract.
99. Sima, A. A. F., Pierson, C. R., and Zhang, W. (2003b) The molecular abnormalities of the paranode in type 1 diabetic polyneuropathy are prevented by C-peptide. Brain Pathol. 12(Suppl. 42), 17, abstract.
100. Sima, A. A. F., and Sugimoto, K. (1999) Experimental diabetic neuropathy: An update. Diabetologia, 42, 773-788.
101. Sima, A. A. F., Thomas, P. K., Ishii, D., and Vinik, A. (1997b) Diabetic neuropathies. Diabetologia, 40(Suppl 3), B74-B77.
102. Sima, A. A. F., Zhang, W., Xu, G., Sugimoto, K., Guberski, D. L., and Yorek, M. A. (2000) A comparison of diabetic polyneuropathy in type-2 diabetic BBZDR/Wor-rat and in type 1 diabetic BB/Wor-rat. Diabetologia, 43, 786-793.
103. Sima, A. A. F., Zhang, W.-X., Sugimoto, K., Henry, D., Li, Z.-G., Wahren, J., et al. (2001b) C-peptide prevents and improves chronic type 1 diabetic neuropathy in the BB/Wor-rat. Diabetologia, 44, 889-897.
104. Soulis, T., Thallas, V., Youssef, S., Gilbert, R. E., McWilliam, B. G., Murray-McIntosh, R. P., et al. (1997) Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia, 40, 619-628.
105. +)-ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat. J. Clin. Invest., 94, 853-859.
106. Stevens, M. J., Lattimer, S. A., Kamijo, M., Van Huysen, C., Sima, A. A. F., and Greene, D. A. (1993) Osmotically-induced nerve taurine depletion and the compatible osmolyte hypothesis in experimental diabetic neuropathy in the rat. Diabetologia, 36, 608-614.
107. Stevens, M., Li, F., Zhang, W., and Sima, A. A. F. (2003) C-peptide prevents impaired endoneurial blood flow but does not effect oxidative stress in type 1 BB/Wor-rats. J. Periph. New Syst., 8, 196.
108. Sugimoto, K., Murakawa, Y., and Sima, A. A. F. (2000a) Diabetic neuropathy - a continuing enigma. Diabetes Metab. Res. Rev., 16, 408-433.
109. Sugimoto, K., Murakawa, Y., Zhang, W.-X., Xu, G., and Sima, A. A. F. (2000b) Insulin receptor in rat peripheral nerve: Its localization and alternatively spliced isoforms. Diabetes Metab. Res. Rev., 16, 354-363.
110. Tesfaye, S., Stevens, L. K., Stephanson, J. M., Fuller, J. H., Plater, M., Ionescu-Tirgoviste, C., et al. (1996) Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: The EURODIAB IDDM Complication Study. Diabetologia, 39, 1377-1384.
111. Thomas, P. K. (1997) Classification, differential diagnosis, and staging of diabetic peripheral neuropathy. Diabetes, 46(Suppl 2), S54-S57.
112. Thomas, P. K., and Eliasson, S. G. (1984) Diabetic neuropathy. In: Peripheral Neuropathy, Edited by Dyck, P. J., Thomas, P. K., Lambert, E. H., and Bunger, R., pp. 1973-1810. Philadelphia, W. B. Saunders.
113. Tomlinson, D. R., and Fernyhough, P. (1999) Neurotrophism in diabetic neuropathy. In: Chronic Complications in Diabetes. Animal Models and Chronic Complications, Edited by Sima, A. A. F., pp. 167-182. Amsterdam, Harwood.
114. Tomlinson, D. R., Fernyhough, P., and Diemel, L. T. (1997) Role of neurotrophins in diabetic neuropathy and treatment with nerve growth factors. Diabetes, 46(Suppl 2), S43-S49.
115. Vinik, A. I., Liuzze, F. J., Holland, M. T., Stansberry, K. B., Lebean, J. M., and Colen, L. B. (1992) Diabetic neuropathies. Diabetes Care, 15, 1926-1975.
116. Vlassara, H., Brownlee, M., and Cerami, A. (1981) Nonenzymatic glycosylation of peripheral nerve protein in diabetes mellitus. Proc. Natl. Acad. Sci. U. S. A., 78, 5190-5192.
117. Vlassara, H., Brownlee, M., and Cerami, A. (1984) Accumulation of diabetic rat peripheral nerve myelin by macrophages increases with the presence of advanced glycosylation endproducts. J. Exp. Med., 160, 197-207.
118. Vlassara, H., Brownlee, M., and Cerami, A. (1985) Recognition and uptake of human diabetic peripheral nerve myelin by macrophages. Diabetes, 34, 553-557.
119. Wahren, J., Ekberg, K., Johansson, J., Henriksson, M., Pramanik, A., Johansson, B.-L., et al. (2000) Role of C-peptide in human physiology. Am. J. Physiol. Endocrinol. Metab., 278, E759-E768.
120. Wallerath, T., Kunt, T., Forst, T., Closs, E., Lehmann, R., Göpfert, A., Pfütgner, A., Beyer, J., and Förstermann, U. (2003) Stimulation of endothelial nitric oxide synthase by proinsulin C-peptide. Am. J. Physiol., in press.
121. Wautier, J. L., Zoukourian, C., Chappey, O., Wautier, M. P., Guillausseau, P. J., Cao, R., et al. (1996) Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J. Clin. Invest., 97, 238-243.
122. Williamson, J. R., Chang, K., Frangos, M., Hasan, K. S., Ido, Y., Kawamura, T., et al. (1993) Hyperglycemic pseudohypoxia and diabetic complications. Diabetes, 42, 801-813.
123. Wuarin, L., Guertin, D. M., and Ishii, D. N. (1994) Early reduction in insulin-like growth factor gene expression in diabetic nerve. Exp. Neurol., 130, 106-114.
124. Xu, G., Murakawa, Y., Pierson, C. R., and Sima, A. A. F. (2002) Altered β-tubulin and neurofilament expression and impaired axonal growth in diabetic nerve regeneration. J. Neuropathol. Exp. Neurol., 61, 164-175.
125. Xu, G., and Sima, A. A. F. (2001) Altered immediate early gene expression is impaired in diabetic nerve: Implications in regeneration. J. Neuropathol. Exp. Neurol., 60, 972-983.
126. Yagihashi, S., Kamijo, M., and Watanabe, K. (1990) Reduced myelinated fiber size correlates with loss of axonal neurofilaments in peripheral nerve of chronically streptozotocin diabetic rats. Am. J. Pathol., 136, 1365-1373.
127. Yoshida, K., Hirokawa, J., Tagami, S., Kawakami, Y., Urata, Y., and Kondo, T. (1995) Weakened cellular scavenging activity against oxidative stress in diabetes mellitus: Regulation of glutathione synthesis and efflux. Diabetologia, 38, 201-210.
128. Zhang, W., Yorek, M., Pierson, C. R., Murakawa, Y., Breidenbach, A., and Sima, A. A. F. (2001) Human C-peptide dose dependently prevents early neuropathy in the BB/Wor-rat. Int. J. Exp. Diabetes Res., 2, 187-194.
129. Zhu, X., and Eichberg, J. (1990) A myo-inositol pool utilized for phosphatidylinositol synthesis is depleted in sciatic nerve from rats with streptozotocin-induced diabetes. Proc. Natl. Acad. Sci. U. S. A., 87, 9818-9822.
130. Zhuang, H. X., Snyder, C. K., Pu, S. F., and Ishii, D. N. (1996) Insulin-like growth factors reverse or arrest diabetic neuropathy: Effects on hyperalgesia and impaired nerve regeneration in rats. Exp. Neurol., 140, 198-205.
131. Zhuang, H. X., Wuarin, L., Fei, Z. J., and Ishii, D. N. (1997) Insulin-like growth factor (IGF) gene expression is reduced in neural tissues and liver from rats with non-insulin-dependent diabetes mellitus, and IGF treatment ameliorates diabetic neuropathy. J. Pharmacol. Exp. Ther., 283, 366-374.
132. Ziegler, D., Reljanovic, M., Meknert, H., and Gries, F. A. (1999) Alpha lipoic acid in the treatment of diabetic polyneuropathy in Germany: Current evidence from clinical trials. Exp. Clin. Endocrinol. Diabetes, 107, 421-430.